Avidity Biosciences shared positive Phase I/II results for del-zota, an antibody-oligonucleotide conjugate showing reversal of Duchenne muscular dystrophy progression after one year of continuous treatment. The improvements include functional measures in patients. Concurrently, the company announced a substantial $500 million public offering, with shares falling following the announcement, dimming speculation of an imminent acquisition by Novartis.